April 11, 2026 10:37 pm (IST)
Follow us:
Strides Arcolab signs agreement with Gilead Sciences
Bangalore/Kolkata, Jan 20 (IBNS): Strides Arcolab Limited (Strides) on Tuesday announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.
As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.
TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead’s Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Nissan Motor India marks major network expansion with 54 new customer touchpoints in Q1 of CY 2026
Fri, Apr 10 2026
Groww shares climb 5%, extend rally for third session
Fri, Apr 10 2026
From Oracle layoffs in the US to an India comeback: Couple’s emotional story goes viral
Fri, Apr 10 2026
South Asia remains fastest-growing region; India continues as growth engine: World Bank
Thu, Apr 09 2026
AI impact: Dell cuts 11,000 jobs in strategic workforce trim
Thu, Apr 09 2026
TCS gains ahead of Q4 earnings; street eyes growth signals
Thu, Apr 09 2026
Meesho shares soar 14% — stock now 55% above IPO price!
Thu, Apr 09 2026